BIOMAT Database Logo BIOMAT Database Logo

[Maintenance chemotherapy using UFT and FT for gynecological malignant tumors. The Gunma Prefectural Society for Study of Chemotherapy for Gynecological Cancer]. 1992

N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
College of Medical Care and Technology, Gunma University.

The Gunma Prefectural Society for Study of Chemotherapy for Gynecological Cancer made a comparative study on postoperative supplementary chemotherapy including UFT and FT-E for gynecological malignant tumors. The number of cases registered totaled 182, which was broken down into ovarian cancer 53 cases, uterine cervical cancer 89 cases and endometrial cancer 30 cases. Complete cases among them consisted of ovarian cancer 53 cases, uterine cervical cancer 86 cases and endometrial cancer 27 cases for a total of 166 cases. Ovarian cancer was stratified into the completely and incompletely removed cases, uterine cervical cancer into postoperative non-irradiated and irradiated cases and endometrial cancer into the positive metastasis (+) group and negative metastasis (-) group. Then the UFT administration group and FT-E administration group were compared for postoperative survival. There were control groups for both ovarian and endometrial cancer. UFT administration showed a significant improvement in the survival rate (P < 0.05) compared to the FT-E administration group in the cases of ovarian cancer completely removed and the cases of endometrial cancer irradiated after operation. No significant difference was observed between other groups compared. The incidence of side effects was 20.6% (20/97) in the UFT administration group and 3.6% (2/55) in the FT-E group. Neither group showed any serious side effects.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.

Related Publications

N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Intraperitoneal chemotherapy using CBDCA for malignant gynecological tumors].
August 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Clinical effects of oral administration of UFT on gynecological malignant tumors].
August 1984, Nihon Sanka Fujinka Gakkai zasshi,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Experiences and results in the chemotherapy of malignant gynecological tumors].
June 1963, Die Medizinische Welt,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[FT-207 maintenance therapy of malignant gynecologic cancer].
August 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Comparative pharmacokinetic study between UFT and FT-207 suppo and phase II studies in gynecological malignancies].
November 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Phase II study of UFT for malignant tumors of urinary organs].
June 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Clinical effect of postoperative adjuvant chemotherapy for advanced colorectal cancer--comparisons of between tegafur (FT) and UFT].
October 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Randomized comparative study of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and UFT-tamoxifen regimens as adjuvant chemotherapy after surgery for breast cancer: Tochigi Prefectural Study Group for Post-Breast Cancer Adjuvant Chemotherapy].
July 2000, Gan to kagaku ryoho. Cancer & chemotherapy,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[Apoptosis and malignant gynecological tumors].
February 1997, Zhonghua fu chan ke za zhi,
N Ohwada, and M Nagayama, and T Kosuge, and T Tsukagoshi, and Y Ibuki, and M Igarashi, and K Yazaki, and T Ito, and Y Nogami, and H Kimura
[A sensitivity test of UFT and FT-207 against human pulmonary cancer using nude mice].
August 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!